Group 1: Business Strategy and Growth - The pharmaceutical business group aims to lead in the injury sector, expand its market presence, and establish a comprehensive operation in the Sanqi industry [2] - The group will deepen academic research and collaborate with various institutions to enhance existing products and explore potential new products [2] - The focus will also be on upstream supply and production coordination to achieve smart manufacturing and cost reduction [2] Group 2: Health Products Performance - The health products business group achieved a revenue of 6.422 billion CNY in 2023, marking a year-on-year growth of 6.50% [3] - Yunnan Baiyao toothpaste holds a 24.60% market share in the domestic market, maintaining its leading position [4] - The health products group recorded significant online sales during the "Double 11" shopping festival, with the flagship store surpassing 100 million CNY in sales for the first time [4] - The anti-hair loss product line, Yangyuanqing, saw a revenue increase of 36%, exceeding 300 million CNY [4] Group 3: Dividend Policy - Yunnan Baiyao's 2023 dividend plan includes a payout of 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which represents 90.53% of the net profit attributable to shareholders [6] - The company has consistently paid dividends for 31 years since its listing, with cumulative cash dividends exceeding 24.4 billion CNY [6] Group 4: R&D Progress in Nuclear Medicine - In 2023, the company made significant advancements in its nuclear medicine pipeline, receiving approval for clinical trials of the INR101 injection [7] - The INR102 project for prostate cancer treatment has completed preliminary studies and initiated pharmaceutical research [7]

Group 1: Investor Relations Activity - The investor relations activity was categorized as a phone survey [1] - Participants included representatives from E Fund Management [1] - The meeting took place on June 28, 2024, at the company's headquarters [1] Group 2: Meeting Purpose - The main purpose of the meeting was to understand the company's production and operational status [1] - The meeting involved discussions with the company's securities affairs representative and investor relations management [1]

具体内容详见公司同日在巨潮资讯网（网址：http://www.cninfo.com.cn） 披露的公告《关于引进 KA-1641 项目的公告》（公告编号：2024-39）。 股票代码：000538 股票简称：云南白药 公告编号：2024-38 云南白药集团股份有限公司 第十届董事会 2024 年第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）第十 届董事会 2024 年第七次会议（以下简称"会议"）于 2024 年 6 月 27 日在 公司总部四楼会议室以现场结合通讯表决的方式召开，本次会议通知于 2024 年 6 月 21 日以书面、邮件或传真方式发出，应出席董事 11 名，实际 出席董事 11 名（其中董事李泓燊先生以通讯表决方式出席会议，独立董事 刘国恩先生、戴扬先生、何勇先生以视频方式出席会议）。本次会议的召集、 召开程序符合《中华人民共和国公司法》《公司章程》的相关规定，会议合 法有效。会议由公司董事长张文学先生主持，与会董事经充分讨论，会议审 议通过如下议案： 一、审议通 ...

股票代码：000538 股票简称：云南白药 公告编号：2024-39 云南白药集团股份有限公司 关于引进 KA-1641 项目的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"云南白药"或"公司"）于 2024 年 6 月 27 日召开公司第十届董事会 2024 年第七次会议，审议通过《关于引 进 KA-1641 项目的议案》，同意公司从康源博创生物科技（北京）有限公司 （以下简称"康源博创"）引进抗体药物 KA-1641（以下简称"标的产品"） 的相关专利，并将在全球范围内对标的产品进行研究开发、生产和商业化活 动，具体情况如下： 一、交易概述 公司与康源博创签订《技术转让协议》（以下简称"《协议》"），根 据《协议》，康源博创将转让其自行研发的抗体药 KA-1641 相关专利至云南 白药（以下简称"该项目"），本次交易首付款为 600 万元，研发和注册里 程碑付款为 3,200 万元，云南白药将在全球范围内对标的产品进行研究开发、 生产和商业化活动。云南白药及康源博创有意在目前研发的基础上继续共同 推动该项目的研发 ...

Group 1: Investor Relations Activity - The meeting was categorized as a "telephone conference" [1] - Participants included representatives from Dymon Asia and Capital (HK) Limited [1] - The meeting took place on June 14, 2024, at the company's headquarters [1] Group 2: Company Overview - The main focus of the meeting was to understand the company's production and operational status [1] - The meeting was attended by the board secretary and investor relations management [1]

Group 1: Investor Relations Activity - The meeting was categorized as a telephone conference [1] - Participants included representatives from Point72 Hong Kong Limited and Haitong International [1] - The meeting took place on June 14, 2024, at the company's headquarters [1] Group 2: Company Overview - The main focus was to understand the company's production and operational status [1] - The meeting was attended by the company's securities representative and investor relations management [1]

Financial Performance - In Q1 2024, the company achieved a revenue of 10.774 billion CNY, a year-on-year increase of 2.49% [2] - The net profit attributable to shareholders was 1.702 billion CNY, up 12.12% year-on-year [2] - The net profit after deducting non-recurring gains and losses reached 1.690 billion CNY, growing by 20.51% [2] - Basic earnings per share were 0.95 CNY, reflecting an 11.76% increase [2] - The weighted average return on equity was 4.18%, an increase of 0.31 percentage points year-on-year [2] Market Position and Online Strategy - In 2023, the health product segment generated a revenue of 6.422 billion CNY, with a year-on-year growth of 6.50% [3] - Yunnan Baiyao toothpaste held a 24.60% market share in the domestic market, maintaining the leading position [3] - During the "Double 11" shopping festival, the health product segment achieved multiple top rankings, with the Yunnan Baiyao Tmall flagship store surpassing 100 million CNY in sales for the first time [3][4] - The company actively engaged in online promotions during major shopping events and collaborated with e-commerce platforms to enhance brand visibility [4] Development Plans for Traditional Chinese Medicine Resources - The Traditional Chinese Medicine Resources Division aims to leverage Yunnan's rich medicinal material resources, focusing on user demand and sustainable supply chain development [5] - The brand medicinal materials segment will expand by enhancing the three-seven industry platform and developing other advantageous medicinal materials [5] - The natural plant extraction segment will refine operations and innovate production techniques to capture market share [5] Overall Business Strategy for 2024 - The company will focus on strategic leadership, emphasizing growth and efficiency in its core pharmaceutical, health, and traditional Chinese medicine resources [7] - The strategy includes optimizing product and industry structures to create new growth points while enhancing internal operational efficiency [7] - The goal is to achieve sustainable growth through a coordinated development of scale, structure, and quality [7]

Group 1: Sales Performance and Growth - Other brand traditional Chinese medicine products achieved significant growth in 2023, with sales of Pudilan Anti-inflammatory Tablets and Huoxiang Zhengqi Water exceeding 100 million yuan, increasing by nearly 16% and 124% year-on-year respectively [1] - The sales revenue of Gonyang Ning Capsules, used for gynecological inflammation, rose by 47% year-on-year [1] - In the oral care sector, Yunnan Baiyao toothpaste maintained a market share of 24.60% in 2023, ranking first in the domestic market [2] Group 2: Marketing Strategies - During the "Double 11" shopping festival, Yunnan Baiyao's official flagship store for toothpaste achieved over 100 million yuan in sales for the first time, becoming the first flagship store to do so with a single toothpaste product [2] - The company implemented a dual-channel strategy, enhancing brand exposure through online and offline promotions, including over 14,700 offline promotional events covering 1,465 cities [2] Group 3: Supply Chain Development - Yunnan Baiyao focuses on long-term strategies for major traditional Chinese medicine varieties, establishing a standardized full industry chain for key medicinal materials like Chuanxiong and Sanqi [3][4] - The company has successfully transformed the wild breeding of Chuanxiong into a marketable and industrialized medicinal material through two decades of efforts [4] Group 4: Investor Returns - Since its listing, Yunnan Baiyao has distributed over 24.4 billion yuan in cash dividends, with a 2023 dividend proposal of 20.77 yuan per 10 shares, totaling 3.706 billion yuan, which accounts for 90.53% of the net profit attributable to shareholders [5] - The company repurchased 12,599,946 shares, approximately 0.7015% of the total share capital, with a repurchase cost exceeding 700 million yuan, and completed the cancellation of these shares in April 2024 [5]

云南白药集团股份有限公司 投资者调研会议记录表 编号：33-2406-03 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑其他（电话会议） Mirae Asset Global Investments Management Limited-Daniel 参与单位名称及人员 ZHOU 姓名 海通国际-孟科含、聂照亿 时间 2024年6 月14日 地点 集团总部办公大楼 上市公司接待人员 董事会秘书-钱映辉、投资者关系管理-张昱 投资者关系活动主要 ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2024 年 6 月 14 日 地点：集团总部办公大楼 召开方式：电话会议 投 资 者 ： Mirae Asset Global Investments Management Limited-Daniel ZHOU，海通国际-孟科含、聂照亿 参加人员：董事会秘书-钱映辉、投资者关系管理-张昱 会议内容 1、请介绍一下公司 2024 年一季度和 2023 年年度业绩情况。 答：2024 年一季度，公司实现营业收入 107.74 亿，同比增长 2.49%； 归母净利润 17.02 亿元，同比增长 12.12%；归母扣非净利润 16.90 亿元，同比增长 20.51%；基本每股收益 0.95 元/股，同比增长 11.76%； 加权平均净资产收益率 4.18%，同比增加 0.31 个百分点。 2023 年，公司全年实现营业收入 391.11 亿元，较上年同期的 364.88 亿元净增 26.23 亿元，增幅 7.19%，其中工业收入增速 7.58%； 实现归母净利润 40.94 亿元，较上年同期的 30.01 亿元上升 10.93 亿 元，增幅 36.41%；归属于 ...